کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2124426 1547254 2008 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Accessibility to targeted oncology drugs in Slovenia and selected European countries
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Accessibility to targeted oncology drugs in Slovenia and selected European countries
چکیده انگلیسی

AimThe aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries.MethodsAccessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated.ResultsThe time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries.ConclusionThe utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 44, Issue 3, February 2008, Pages 408–418
نویسندگان
, , ,